Core Insights - BioNexus Gene Lab Corp (BGLC) has entered into a non-binding Strategic Partnership Term Sheet with BirchBioMed Inc. to advance the FS2 topical platform and enhance BGLC's biotech presence in Asia [1][2] Group 1: Partnership Details - BGLC will lead Birch's upcoming USD 10 million financing round through a strategic equity investment, aiming to accelerate the commercialization of Birch's FS2 topical platform in Southeast Asia [2] - The partnership combines BGLC's regional market access and infrastructure with Birch's innovative science in dermal regeneration and fibrosis control [2][5] Group 2: Proposed Terms - The Term Sheet is non-binding except for exclusivity and confidentiality provisions, which are binding for 60 days from execution [4] - BGLC will issue common shares representing 4.99 percent of its outstanding shares to Birch as part of the investment, while Birch will issue 1.5 million common shares to BGLC [9] Group 3: Strategic Support and Next Steps - BGLC will provide Birch with market intelligence, regulatory and clinical-trial strategy guidance, and assistance in securing licensees and commercialization partners for the FS2 topical cream in Malaysia and Singapore [9] - Both parties plan to negotiate a definitive agreement that includes customary representations, warranties, and closing conditions [9]